Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ci 716
2. Ci-716
3. Ci716
4. Flupyrazapon
5. Flupyrazopon
6. Hydrochloride, Zolazepam
7. Zolasepam
8. Zolazepam
1. Zolazepam Hcl
2. 33754-49-3
3. Ci-716
4. 45sj093q1n
5. 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one;hydrochloride
6. 4-(o-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1h)-one Monohydrochloride
7. Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, Monohydrochloride
8. Unii-45sj093q1n
9. Zolazepam Hydrochloride [usan]
10. Einecs 251-668-7
11. Zolazepam Hydrochloride [usan:usp]
12. Schembl73002
13. Zolazepam Hydrochloride (usp)
14. Chembl2107559
15. Dtxsid00955349
16. Zolazepam Hydrochloride(500 Mg)
17. Zolazepam Hydrochloride [mi]
18. Zolazepam Hydrochloride [usp-rs]
19. Zolazepam Hydrochloride [green Book]
20. Ft-0775057
21. Zolazepam Hydrochloride [usp Impurity]
22. D06377
23. Zolazepam Hydrochloride [usp Monograph]
24. Q27258863
25. 4-(2-fluorophenyl)-1,3,8-trimethyl-6h-pyrazolo[3,4-e][1,4]diazepin-7-one,hydrochloride
26. 4-(2-fluorophenyl)-1,3,8-trimethyl-6,8-dihydropyrazolo[3,4-e][1,4]diazepin-7(1h)-one--hydrogen Chloride (1/1)
27. 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1h)-one Monohydrochloride
28. 42551-17-7
29. Pyrazolo(3,4-e)(1,4)diazepin-7(1h)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, Hydrochloride
Molecular Weight | 322.76 g/mol |
---|---|
Molecular Formula | C15H16ClFN4O |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 1 |
Exact Mass | 322.0996670 g/mol |
Monoisotopic Mass | 322.0996670 g/mol |
Topological Polar Surface Area | 50.5 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 455 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Anxiety Agents
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 54382-127
Start Marketing Date : 2011-09-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5298
Submission : 1990-01-24
Status : Active
Type : II
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?